Financials
Financial year 2024
Sterop Overseas from Anderlecht, company number BE0419184411, closed financial year 2024 with a result of € 1 million after tax. For that financial year Sterop Overseas recorded a gross margin of € 1.9 million and equity of € 2.3 million. Compared with financial year 2023, the result moved from € 460,854 to € 1 million. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on October 17, 2025.
€ 2.3 million
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 1 million
▲ 124% vs 2023
Profit after tax over the fiscal year.
€ 87,657
▼ 83% vs 2023
Cash and bank balances on the last day of the fiscal year.
€ 1 million paid out
100 % of the profit went to the shareholders, mostly to PHARMASOVA (100 % of the shares). That is where the money ends up.
People and assets in 2024
5.4
Average over the fiscal year, from the social balance sheet.
€ 265,575
▼ 11% vs 2023
€ 49,200 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2024
€ 350,000
▲ 133% vs 2023
Loans from banks and other lenders, long and short.
€ 895,525
▼ 32% vs 2023
Supplier invoices still open on the last day of the fiscal year.
€ 159,571
▲ 178% vs 2023
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2021 | 2022 | 2023 | 2024 | Change 2023 → 2024 | |
|---|---|---|---|---|---|
| Gross margin | € 1,395,701 | € 1,280,726 | € 1,259,038 | € 1,869,081 | ▲ 48% |
| Profit after taxes | € 875,563 | € 336,289 | € 460,854 | € 1,031,504 | ▲ 124% |
| Equity | € 2,338,645 | € 2,344,934 | € 2,345,788 | € 2,347,292 | |
| Total debts | € 2,408,935 | € 3,690,900 | € 2,976,692 | € 2,881,897 | ▼ 3% |
| Cash | € 1,410,743 | € 859,249 | € 516,144 | € 87,657 | ▼ 83% |
| Retained profit | € 2,258,645 | € 2,264,934 | € 2,265,788 | € 2,267,292 | |
| Dividend | € 10,395,000 | € 330,000 | € 460,000 | € 1,030,000 | ▲ 124% |
| Bank debt | € 0 | € 0 | € 150,000 | € 350,000 | ▲ 133% |
| Balance sheet total | € 4,747,580 | € 6,035,834 | € 5,322,480 | € 5,229,189 | ▼ 2% |
| Employees (FTE) | 5.6 | 4.7 | - | 5.4 |
Key figures of Sterop Overseas, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.
What happened to Sterop Overseas?
What happened at Sterop Overseas in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2024: profit of € 1 million (▲ 124% vs 2023). filed late Source: NBB ↗
- Daniel CATOUL became a director. NBB
- E2A PARTNERS SRL became a director. NBB
- Rita LABIS became a director. NBB
- Start of the company according to the CBE. KBO
- New establishment in Anderlecht. KBO
In short
From € 875,563 profit in 2021 to € 1 million profit in 2024.
Paid € 950,103 in corporate taxes since 2021.
Best year ever: 2024, with € 1 million profit.
On average € 346,100 of value added per employee in 2024.
A new publication or filing at Sterop Overseas? We notify you, reason included.
Follow Sterop OverseasDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of PHARMASOVA comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
Sterop OverseasBehind Sterop Overseas are Rita LABIS, Daniel CATOUL and E2A PARTNERS SRL. The shares are held by PHARMASOVA (100%).
Directors
According to the 2024 annual accounts
Rita LABIS
Director
since 2017
Daniel CATOUL
Director
Also active at: Laboratoires Belges Pharmacobel, Etablissements Medi-Labo, C.D. & ASSOCIES, Leo Keller en Zonen, Laboratoires Sterop, T.DIFFUSION, ALTERNATIV WORKSPACE SOLUTIONS, S.A. Laboratoires Pharmaceutiques Trenker +7 more
since 2021
Managing director · represented by Sophie EYKERMAN
Also active at: Laboratoires Belges Pharmacobel, Etablissements Medi-Labo, Laboratoires Sterop, PHARMASOVA
since 2021
Shareholders
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Researchdreef 20
1070 Anderlecht
Scheutlaan 46 5
1070 Anderlecht
Active since 25 January 1979
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0419.184.411
- VAT number
- BE 0419.184.411
- Registered office
- Researchdreef 20, 1070 Anderlecht
- Names & denominations
- Sterop Overseas
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 27 January 1979
- Peppol
- Active · Active since 12 Mar 2026
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Groothandel in farmaceutische producten
Groothandel in chemische producten voor industrieel gebruik
Groothandel in chemische producten